BOTANIX PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.235 AUD | +6.82% |
|
+9.30% | +23.68% |
| Mar. 18 | Botanix Pharmaceuticals Limited(ASX:BOT) added to S&P/ASX All Ordinaries Index | CI |
| Feb. 27 | Botanix Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: Juni | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 83.32 | 139.3 | 37.94 | 77.85 | 55.47 | 170.6 |
| Enterprise Value (EV) 1 | 66.05 | 134.6 | 13.71 | 56.56 | 48.31 | 160.4 |
| P/E ratio | -4.87 x | -8.03 x | -2.18 x | -23.4 x | -4.21 x | -16.4 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 46.9 x | 29.7 x | 5.02 x | 11.3 x | 20.1 x | 45.2 x |
| EV / Revenue | 37.2 x | 28.7 x | 1.81 x | 8.21 x | 17.5 x | 42.5 x |
| EV / EBITDA | - | -7,846,006 x | -821,819 x | -16,813,796 x | -3,668,488 x | -17,611,784 x |
| EV / FCF | -11.2 x | -19.8 x | -1.23 x | -31.8 x | -5.37 x | -10.3 x |
| FCF Yield | -8.9% | -5.05% | -81% | -3.15% | -18.6% | -9.71% |
| Price to Book | 5.12 x | 227 x | 1.6 x | 3.74 x | 6.81 x | 7.43 x |
| Nbr of stocks (in thousands) | 757,425 | 774,028 | 972,698 | 973,142 | 973,142 | 1,312,460 |
| Reference price 2 | 0.1100 | 0.1800 | 0.0390 | 0.0800 | 0.0570 | 0.1300 |
| Announcement Date | 9/21/18 | 8/19/19 | 8/31/20 | 8/26/21 | 9/16/22 | 9/29/23 |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Juni | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1.778 | 4.686 | 7.564 | 6.887 | 2.755 | 3.772 |
| EBITDA | - | -17.16 | -16.68 | -3.364 | -13.17 | -9.106 |
| EBIT 1 | -11.16 | -17.16 | -16.7 | -3.38 | -13.19 | -9.126 |
| Operating Margin | -627.86% | -366.19% | -220.72% | -49.08% | -478.66% | -241.93% |
| Earnings before Tax (EBT) 1 | -11.01 | -17.04 | -16.73 | -3.334 | -13.17 | -9.154 |
| Net income 1 | -11.01 | -17.04 | -16.73 | -3.334 | -13.17 | -9.154 |
| Net margin | -619.37% | -363.63% | -221.19% | -48.41% | -478.1% | -242.66% |
| EPS 2 | -0.0226 | -0.0224 | -0.0179 | -0.003426 | -0.0135 | -0.007932 |
| Free Cash Flow 1 | -5.882 | -6.805 | -11.11 | -1.779 | -8.997 | -15.57 |
| FCF margin | -330.83% | -145.22% | -146.83% | -25.83% | -326.58% | -412.7% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 9/21/18 | 8/19/19 | 8/31/20 | 8/26/21 | 9/16/22 | 9/29/23 |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 17.3 | 4.7 | 24.2 | 21.3 | 7.16 | 10.3 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -5.88 | -6.8 | -11.1 | -1.78 | -9 | -15.6 |
| ROE (net income / shareholders' equity) | -101% | -202% | -138% | -15% | -91% | -58.9% |
| ROA (Net income/ Total Assets) | -59.1% | -93.6% | -68.4% | -8.94% | -45.8% | -29.3% |
| Assets 1 | 18.64 | 18.2 | 24.46 | 37.29 | 28.76 | 31.19 |
| Book Value Per Share 2 | 0.0200 | 0 | 0.0200 | 0.0200 | 0.0100 | 0.0200 |
| Cash Flow per Share 2 | 0.0200 | 0.0100 | 0.0300 | 0.0200 | 0.0100 | 0.0100 |
| Capex | - | 0.01 | 0.09 | 0.01 | 0.01 | 0.01 |
| Capex / Sales | - | 0.28% | 1.19% | 0.12% | 0.26% | 0.2% |
| Announcement Date | 9/21/18 | 8/19/19 | 8/31/20 | 8/26/21 | 9/16/22 | 9/29/23 |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +23.68% | 225M | |
| +12.55% | 9B | |
| -12.75% | 4.96B | |
| +42.38% | 4.47B | |
| +5.23% | 3.9B | |
| +20.51% | 2.45B | |
| -19.05% | 2.41B | |
| -28.72% | 2.23B | |
| +11.13% | 2.02B | |
| +4.18% | 1.65B |
- Stock Market
- Equities
- BOT Stock
- Financials Botanix Pharmaceuticals Limited
